DocWire News Editors

DocwireNews

Asthma exacerbations are common, costly, and may lead to progressive loss of lung function over time, as well as increase disease severity over time. When patients with asthma are in the &ldquo;yellow zone,&rdquo; clinicians often need to act quickly to help their patients regain control of their asthma symptoms. There is a need to better understand what treatments are appropriate in the short-term while patients are in the yellow zone. To help clarify the differences in treatment between children and adults while in the yellow zone, Daniel Jackson, MD, an Associate Professor of Pediatrics from the University of Wisconsin-Madison, School of Medicine and Public Health, presented on &ldquo;Dose Escalation of Inhaled Corticosteroids (ICS) to Prevent Exacerbations&mdash;Children&nbsp;Versus&nbsp;Adults.&rdquo;The National Asthma Education and Prevention Program (NAEPP) Guidelines for the Diagnosis and Management of Asthma (EPR-3) recommend the following treatments for patients in the yellow zone: increasing the use of short-acting beta agonists (SABA) and not doubling ICS use (although quadrupling ICS use may be beneficial). To assess whether quintupling the ICS dose when patients are in the yellow zone was effective, Dr. Jackson and his colleagues performed a blinded, randomized clinical trial in children aged 5 to 11 years with mild to moderate asthma and a history of exacerbations, who were treated with low-dose ICS.The trial randomized participants to a high-dose ICS arm and a low-dose ICS arm, where the participants used low dose ICS daily and were assigned either high dose ICS (5x) or low dose ICS when they had an asthma exacerbation. The primary outcome was the rate of asthma exacerbations, with secondary outcomes of time to first asthma exacerbation treated with oral corticosteroids, rate of treatment failure, symptoms during yellow zone episodes, albuterol use during yellow zone episodes, and growth. Of 444 enrolled participants, 192 participants completed the study with 98 in the low-dose ICS arm and 94 in the hig- dose ICS arm. There were no significant differences between study arms for the rate of asthma exacerbations, as well as the other secondary outcomes (except for growth). A dose-response effect on growth was observed in younger children, and a significant decrease in growth was observed in the high dose ICS arm.Based on these results, Dr. Jackson urged that &ldquo;[t]he routine use of this strategy [quintupling ICS dose] in asthma treatment plans should be reconsidered.&rdquo;Another recently published study in the New England Journal of Medicine by McKeever et al.1 used a different study design. Its authors examined the quadrupling ICS dose in aborting asthma exacerbations in adolescents and adults with persistent asthma and a history of exacerbations treated with ICS and with/without long-acting beta agonists (LABA). This was an unblinded pragmatic clinical trial that separated participants into a quadrupling group and a non-quadrupling group. The primary outcome was time to exacerbation, which resulted in a statistically significant difference between groups with a relative risk of 0.81 for exacerbations for participants in the quadrupling arm. The authors concluded that quadrupling the ICS dose to control asthma exacerbations may not be clinically meaningful given the potential toxicity from ICS.The results from both of these studies suggest that the clinical relevance for increased ICS dosing in the yellow zone should be reconsidered.Citations<ol>
<li>McCeever T, Mortimer K, Wilson A, et al. N Engl J Med. 2018; 378:902-910.</li>
</ol>&nbsp;

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Dose Escalation of ICS to Prevent Exacerbations? Children Versus Adults

ACAAI 2018

Asthma exacerbations are common, costly, and may lead to progressive loss of lung function over time, as well as increase disease severity over time. When patients with asthma ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe